

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中國動物保健品有限公司*

(Incorporated in Bermuda with limited liability)
(Hong Kong Stock code: 0940)

- (1) **ENGAGEMENT OF INTERNAL CONTROL CONSULTANT**
- (2) **UPDATE ON RECENT DEVELOPMENT OF SUSPENSION OF TRADING**
- (3) **CONTINUAL SUSPENSION OF TRADING**

This announcement is made by China Animal Healthcare Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 10 July 2015, 23 October 2015, 30 October 2015, 30 November 2015, 28 December 2015, 30 December 2015, 1 February 2016, 3 March 2016, 5 April 2016, 4 May 2016, 17 May 2016, 17 October 2016 and 13 January 2017 (the “**Previous Announcements**”) in relation to, among other things, the Forensic Investigation and the suspension of trading of the shares of the Company. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as defined in the Previous Announcements.

(1) ENGAGEMENT OF INTERNAL CONTROL CONSULTANT

As disclosed in the Company's announcement dated 10 July 2015, in order to resume trading in the Company's shares on the Stock Exchange, the Company is required, amongst others, to demonstrate that the Company has put in place adequate financial reporting procedures and internal control systems to meet its Listing Rules obligations. In this connection, the Company has formally engaged SHINEWING Risk Services Limited ("SHINGWING" or "**Internal Control Consultant**") as its internal control consultant to review and advise on the Company's financial reporting procedures and internal control systems.

(2) UPDATE ON RECENT DEVELOPMENT OF SUSPENSION OF TRADING

The Company is currently working with its advisers to take the necessary steps to fulfill the Resumption Conditions imposed by the Stock Exchange as set out in the announcement dated 10 July 2015 and, for such purpose, obtaining comments or opinions from its advisers. As at the date of this announcement, the Forensic Accountant is still in the process of conducting the Forensic Investigation and the Internal Control Consultant is in the process of conducting internal control review. The Company will make further announcement of any material development on the above matters as and when appropriate.

(3) CONTINUAL SUSPENSION OF TRADING

At the request of the Company, the shares of the Company have been suspended from 9 a.m. on 30 March 2015. Trading in the Company's shares will continue to suspend until further notice.

Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

By order of the Board
China Animal Healthcare Ltd.
Wang Yangang
*Chairman, Executive Director
and Chief Executive Officer*

Hong Kong, 15 February 2017

As at the date of announcement, the executive Directors are Mr. Wang Yangang, Mr. Li Jun and Ms. Song Yanmei; and the independent non-executive Directors are Mr. Cai Huiyi, Mr. Liu Zhanmin and Mr. Zhang Suqiang.

** For identification purpose only*